How Novartis Is Helping Staff Through COVID-19 Crisis
Initiatives To Cope For A World In Lockdown
Speaking to Scrip, Steven Baert, chief people and organization officer at Novartis, said that a company’s response to coronavirus reveals its real identity and will shape its future.
You may also be interested in...
Susanne Schaffert tells Scrip that policies of prioritizing coronavirus treatment to the detriment of cancer care was a worrying move that is negatively impacting survival and mortality.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.
A coronavirus vaccine is some way off and until then, Vas Narasimhan, head of Novartis, is thinking that of the drugs being repurposed to treat COVID-19, hydroxychloroquine looks best placed to provide the quickest benefit.